• I am an Associate Scientist and Clinical Investigator at the UAB Comprehensive Cancer Center. Through this role, I have access to all clinical trials being conducted at UAB for all cancer types. As an active member of the Eastern Cooperative Oncology Group (ECOG), I likewise have access to a broad array of national cooperative group clinical trials for most malignancies, including breast, colon, lung and prostate cancer among others.

    I have special research interests in the areas of melanoma skin cancer and sarcomas of soft tissue and bone. I have cared for the great majority of such patients requiring chemotherapy at UAB for the past twelve years. I receive melanoma and sarcoma patient referrals from seven southeastern states and beyond. We offer a variety of sarcoma clinical trials for which I am the local principal investigator. I also serve as the local principal investigator for an array of melanoma clinical trials in both the adjuvant (preventative) and metastatic settings. Our group at UAB is typically among the top three centers nationally and internationally for patient enrollment on melanoma trials. I also chair a Melanoma and Sarcoma Working Group which facilitates multidisciplinary interaction between surgeons, radiation oncologist and medical oncologist for patient care and research.
  • Selected Publications

    Academic Article

    Year Title Altmetric
    2020 Continuous versus intermittent BRAF and MEK inhibition in patients with BRAF-mutated melanoma: a randomized phase 2 trialNature Medicine.  26:1564-1568. 2020
    2020 Pimasertib versus dacarbazine in patients with unresectable NRAS-mutated cutaneous melanoma: Phase II, randomized, controlled trial with crossoverCancers.  12:1-11. 2020
    2020 Control and Toxicity in Melanoma Versus Other Brain Metastases in Response to Combined Radiosurgery and PD-(L)1 Immune Checkpoint InhibitionAdvances in Radiation Oncology2020
    2019 Talimogene laherparepvec induces durable response of regionally advanced Merkel cell carcinoma in 4 consecutive patientsJAAD Case Reports.  5:782-786. 2019
    2019 Observational study of talimogene laherparepvec use for melanoma in clinical practice in the United States (COSMUS-1).Melanoma Management.  6:MMT19. 2019
    2019 Incidence, features and management of radionecrosis in melanoma patients treated with cerebral radiotherapy and anti-PD-1 antibodiesPigment Cell and Melanoma Research.  32:553-563. 2019
    2019 Pathological complete response after neoadjuvant pembrolizumab and radiationClinical and Experimental Dermatology.  44:570-573. 2019
    2019 E3611—A randomized phase II study of ipilimumab at 3 or 10 mg/kg alone or in combination with high-dose interferon-a2b in advanced melanomaClinical Cancer Research.  25:524-532. 2019
    2019 Clinical characterization of colitis arising from anti-PD-1 based therapyOncoImmunology.  8. 2019
    2019 Correlates of response and outcomes with talimogene laherperpvecJournal of Surgical Oncology.  120:558-564. 2019
    2018 Sorafenib for advanced and refractory desmoid tumorsNew England Journal of Medicine.  379:2417-2428. 2018
    2018 Quantitative spatial profiling of PD-1/PD-L1 interaction and HLA-DR/IDO-1 predicts improved outcomes of anti-PD-1 therapies in metastatic melanomaClinical Cancer Research.  24:5250-5260. 2018
    2018 Phase Ib/II, open label, multicenter, study of the combination of SD-101 and pembrolizumab in patients with advanced melanoma who are naïve to anti-PD-1 therapyAnnals of Oncology.  29:viii736. 2018
    2018 Malignant Ewing-Like Neoplasm With an EWSR1-KLF15 Fusion: At the Crossroads of a Myoepithelial Carcinoma and a Ewing-Like Sarcoma. A Case Report With Treatment OptionsInternational Journal of Surgical Pathology.  26:440-447. 2018
    2018 MAGE-A3 immunotherapeutic as adjuvant therapy for patients with resected, MAGE-A3-positive, stage III melanoma (DERMA): a double-blind, randomised, placebo-controlled, phase 3 trial 2018
    2018 Talimogene laherparepvec: First in class oncolytic virotherapyHuman Vaccines and Immunotherapeutics.  14:839-846. 2018
    2018 Adjuvant vemurafenib in resected, BRAFV600 mutation-positive melanoma (BRIM8): a randomised, double-blind, placebo-controlled, multicentre, phase 3 trial 2018
    2018 Acute inflammatory thyromegaly following checkpoint inhibition: A new imaging entity?Radiology Case Reports.  13:89-91. 2018
    2018 Chronic granulomatous dermatitis induced by talimogene laherparepvec therapy of melanoma metastasesJournal of Cutaneous Pathology.  45:48-53. 2018
    2017 Smoldering myocarditis following immune checkpoint blockadeJournal for ImmunoTherapy of Cancer.  5. 2017
    2017 Inflammatory melanoma in transit metastases with complete response to talimogene laherparepvecJAAD Case Reports.  3:280-283. 2017
    2017 Talimogene laherparepvec for regionally advanced Merkel cell carcinoma: A report of 2 casesJAAD Case Reports.  3:185-189. 2017
    2017 Phase III randomized study of 4 weeks of high-dose interferon-α-2b in stage T2bNO, T3a-bNO, T4a-bNO, and T1-4N1a-2a (microscopic) melanoma: A trial of the Eastern Cooperative Oncology Group-American College of Radiology Imaging Network Cancer Research Group (E1697)Journal of Clinical Oncology.  35:885-892. 2017
    2017 Complete response of mediastinal clear cell sarcoma to pembrolizumab with radiotherapy.Clinical Sarcoma Research.  7:14. 2017
    2017 Response of BRAF inhibitor-associated squamous cell lung carcinoma to drug withdrawal 2017
    2016 Primary Sellar Rhabdomyosarcoma Arising in Association with a Pituitary AdenomaInternational Journal of Surgical Pathology.  24:753-756. 2016
    2016 Primary intraosseous smooth muscle tumor of uncertain malignant potential: Original report and molecular characterizationRare Tumors.  8:155-158. 2016
    2016 Radiotherapy to Control Limited Melanoma Progression Following IpilimumabJournal of Immunotherapy.  39:373-378. 2016
    2016 Responses to immune checkpoint inhibitors in nonagenariansOncoImmunology.  5. 2016
    2016 Safety and efficacy of anti-PD-1 in patients with baseline cardiac, renal, or hepatic dysfunctionJournal for ImmunoTherapy of Cancer.  4. 2016
    2016 Pimasertib (PIM) versus dacarbazine (DTIC) in patients (pts) with cutaneous NRAS melanoma: a controlled, open-label phase II trial with crossoverAnnals of Oncology.  27:vi389. 2016
    2016 A phase 2 study of radiosurgery and temozolomide for patients with 1 to 4 brain metastasesAdvances in Radiation Oncology.  1:83-88. 2016
    2016 Zoledronic acid in metastatic osteosarcoma: encouraging progression free survival in four consecutive patients.Clinical Sarcoma Research.  6:6. 2016
    2015 Phase I dose-escalating trial of Escherichia coli purine nucleoside phosphorylase and fludarabine gene therapy for advanced solid tumorsAnnals of Oncology.  26:1481-1487. 2015
    2015 Ipilimumab-induced encephalopathy with a reversible splenial lesionCancer Immunology Research.  3:598-601. 2015
    2015 A randomized, controlled phase III trial of nab-Paclitaxel versus dacarbazine in chemotherapy-naïve patients with metastatic melanomaAnnals of Oncology.  26:2267-2274. 2015
    2014 Induction vemurafenib followed by consolidative radiation therapy for surgically incurable melanoma 2014
    2014 Dacarbazine with or without oblimersen (a Bcl-2 antisense oligonucleotide) in chemotherapy-naive patients with advanced melanoma and low-normal serum lactate dehydrogenase: 'The AGENDA trial' 2014
    2014 Response of follicular dendritic cell sarcoma to gemcitabine and docetaxel: report of two cases and literature review.Clinical Sarcoma Research.  4:6. 2014
    2013 ECOG phase II trial of graded-dose peginterferon a-2b in patients with metastatic melanoma overexpressing basic fibroblast growth factor (E2602)Clinical Cancer Research.  19:6597-6604. 2013
    2012 Nonmalignant cutaneous findings associated with vemurafenib use in patients with metastatic melanomaJournal of The American Academy of Dermatology.  67:1375-1379. 2012
    2011 Extended schedule, escalated dose temozolomide versus dacarbazine in stage IV melanoma: Final results of a randomised phase III study (EORTC 18032)European journal of cancer.  47:1476-1483. 2011
    2011 gp100 peptide vaccine and interleukin-2 in patients with advanced melanomaNew England Journal of Medicine.  364:2119-2127. 2011
    2011 Phase 3 study of docosahexaenoic acid-paclitaxel versus dacarbazine in patients with metastatic malignant melanomaAnnals of Oncology.  22:787-793. 2011
    2008 Combination chemotherapy and ALVAC-CEA/B7.1 vaccine in patients with metastatic colorectal cancerClinical Cancer Research.  14:4843. 2008
    2006 A phase I study of an anti-GD3 monoclonal antibody, KW-2871, in patients with metastatic melanomaCancer Biotherapy and Radiopharmaceuticals.  21:561-568. 2006
    2006 Anti-GD3 monoclonal antibody effects on lymphocytes and antibody-dependent cellular cytotoxicityCancer Biotherapy and Radiopharmaceuticals.  21:553-560. 2006
    2006 Bcl-2 antisense (oblimersen sodium) plus dacarbazine in patients with advanced melanoma: The oblimersen melanoma study groupJournal of Clinical Oncology.  24:4738-4745. 2006
    2005 Phase I study of the intratumoral administration of recombinant canarypox viruses expressing B7.1 and interleukin 12 in patients with metastatic melanomaClinical Cancer Research.  11:4168-4175. 2005
    2005 Intratumoral administration of a recombinant canarypox virus expressing interleukin 12 in patients with metastatic melanomaHuman Gene Therapy.  16:91-100. 2005
    2005 Phase I study of a plasmid DNA vaccine encoding MART-1 in patients with resected melanoma at risk for relapseJournal of Immunotherapy.  28:382-388. 2005
    2004 Immunization of colorectal cancer patients with recombinant baculovirus-derived KSA (Ep-CAM) formulated with monophosphoryl lipid a in liposomal emulsion, with and without granulocyte-macrophage colony-stimulating factorVaccine.  22:773-780. 2004
    2002 Safety and immunogenicity of a DNA vaccine encoding carcinoembryonic antigen and hepatitis B surface antigen in colorectal carcinoma patientsClinical Cancer Research.  8:2782-2787. 2002
    2000 Development of a Polynucleotide Vaccine from Melanoma Antigen Recognized by T Cells-1 and Recombinant Protein from Melanoma Antigen Recognized by T Cells-1 for Melanoma Vaccine Clinical TrialsJournal of Immunotherapy.  23:379-386. 2000
    2000 Human autoantibodies to carcinoembryonic antigen (CEA) induced by a vaccinia-CEA vaccineClinical Cancer Research.  6:34-41. 2000
    2000 Induction of anti-tumor immunity by intrasplenic administration of a carcinoembryonic antigen DNA vaccineJournal of Gene Medicine.  2:135-140. 2000
    2000 SEREX analysis for tumor antigen identification in a mouse model of adenocarcinomaCancer Gene Therapy.  7:446-455. 2000
    1999 Phase I trial of a recombinant vaccinia virus encoding carcinoembryonic antigen in metastatic adenocarcinoma: Comparison of intradermal versus subcutaneous administrationClinical Cancer Research.  5:2330-2337. 1999
    1998 Polynucleotide immunization of nonhuman primates against carcinoembryonic antigenClinical Cancer Research.  4:2903-2912. 1998
    1998 Effects of a novel purine nucleoside phosphorylase inhibitor, BCX-34, on activation and proliferation of normal human lymphoid cells 1998
    1997 Immunization with a plasmid expressing pneumococcal surface protein A (PspA) can elicit protection against fatal infection with Streptococcus pneumoniae 1997
    1997 Incorporation of β-globin untranslated regions into a Sindbis virus vector for augmentation of heterologous mRNA expression 1997
    1996 Phase Ia trial of a polynucleotide anti-tumor immunization to human carcinoembryonic antigen in patients with metastatic colorectal cancerHuman Gene Therapy.  7:755-772. 1996
    1996 Polynucleotide-mediated immunization therapy of cancerSeminars in Oncology.  23:135-147. 1996
    1996 Selected strategies to augment polynucleotide immunization 1996
    1995 A sindbis virus mRNA polynucleotide vector achieves prolonged and high level heterologous gene expression in vivoNucleic Acids Research.  23:1495-1501. 1995
    1995 A carcinoembryonic antigen polynucleotide vaccine has in vivo antitumor activity 1995
    1995 A carcinoembryonic antigen polynucleotide vaccine for human clinical use.Cancer Gene Therapy.  2:33-38. 1995
    1995 Characterization of a Messenger RNA Polynucleotide Vaccine VectorCancer Research.  55:1397-1400. 1995
    1995 Phase I trial of an anti-cd19 deglycosylated ricin a chain immunotoxin in non-hodgkin's lymphoma: Effect of an intensive schedule of administrationJournal of Immunotherapy.  18:231-241. 1995
    1994 Intracellular single-chain antibody directed against erbB2 down-regulates cell surface erbB2 and exhibits a selective anti-proliferative effect in erbB2 overexpressing cancer cell lines 1994
    1994 Immune Response to a Carcinoembryonic Antigen Polynucleotide VaccineCancer Research.  54:1164-1168. 1994
    1994 Characterization of Poliovirus Replicons Encoding Carcinoembryonic AntigenCancer Research.  54:6359-6364. 1994
    1994 Human immune respone to monoclonal antibodiesJournal of Immunotherapy.  15:42-52. 1994
    1994 Optimization of methods to achieve mRNA-mediated transfection of tumor cells in vitro and in vivo employing cationic liposome vectors.Cancer Gene Therapy.  1:245-252. 1994
    1993 An animal model to predict the immunogenicity of murine V regions in humansHuman Antibodies.  4:174-180. 1993
    1992 Lack of T-Cell Immunity in Humans with Preexisting Anti-Mouse Immunoglobulin ReactivityCancer Research.  52:6979-6982. 1992
    1987 Anorexia, fever, murmur, and ocular symptoms in a 56-year-old manPrimary cardiology.  13:69-73. 1987

    Research Overview

  • As a hematologist/oncologist serving on the UAB faculty for over 15 years, I have extensive experience managing virtually all types of cancer. I have particular interest and experience in the management of breast, lung, colon and prostate cancer as well as melanoma and sarcoma.
  • Principal Investigator On

  • Private Grant  awarded by Novartis Pharma AG 2013 - 2024
  • Private Grant  awarded by REPLIMUNE INC. 2019 - 2024
  • Private Grant  awarded by BRISTOL-MYERS SQUIBB COMPANY 2020 - 2023
  • Private Grant  awarded by AMGEN, INC. 2018 - 2023
  • Private Grant  awarded by IDERA PHARMACEUTICALS, INC. 2018 - 2023
  • Private Grant  awarded by F.Hoffmann-La Roche Ltd. 2017 - 2022
  • Private Grant  awarded by AMGEN, INC. 2016 - 2021
  • Private Grant  awarded by AMGEN, INC. 2016 - 2021
  • Private Grant  awarded by ELIOS THERAPEUTICS 2016 - 2021
  • Private Grant  awarded by ELIOS THERAPEUTICS 2015 - 2021
  • Private Grant  awarded by AMGEN, INC. 2015 - 2021
  • Private Grant  awarded by GlaxoSmithKline 2012 - 2020
  • Private Grant  awarded by DYNAVAX TECHNOLOGIES CORPORATION 2017 - 2020
  • Private Grant  awarded by CYTRX CORPORATION 2014 - 2019
  • Private Grant  awarded by F.Hoffmann-La Roche Ltd. 2012 - 2019
  • Private Grant  awarded by TRACON PHARMACEUTICALS, INC. 2013 - 2018
  • Private Grant  awarded by AMGEN, INC. 2017 - 2018
  • Private Grant  awarded by Novartis Pharma AG 2014 - 2018
  • Private Grant  awarded by MERCK & COMPANY, INC. 2013 - 2017
  • Private Grant  awarded by Novartis Pharma AG 2011 - 2017
  • Private Grant  awarded by NOVARTIS PHARMACEUTICALS CORPORATION 2014 - 2017
  • Private Grant  awarded by GENOPTIX, INC. 2016
  • Private Grant  awarded by EMD SERONO 2012 - 2016
  • Private Grant  awarded by F.Hoffmann-La Roche Ltd. 2013 - 2016
  • Private Grant  awarded by GlaxoSmithKline 2009 - 2015
  • Private Grant  awarded by SCHERING PLOUGH CORPORATION 2007 - 2014
  • Private Grant  awarded by ABRAXIS BIOSCIENCES, INC. 2009 - 2014
  • Private Grant  awarded by EISAI, INC. 2010 - 2014
  • Private Grant  awarded by GlaxoSmithKline 2008 - 2013
  • Private Grant  awarded by F.Hoffmann-La Roche Ltd. 2010 - 2013
  • Private Grant  awarded by ZIOPHARM, ONCOLOGY, INC. 2011 - 2013
  • Private Grant  awarded by ARIAD PHARMACEUTICALS, INC. 2008 - 2013
  • Private Grant  awarded by ABBVIE INC 2009 - 2012
  • Private Grant  awarded by ONYX PHARMACEUTICALS, INC. 2005 - 2011
  • Private Grant  awarded by ELI LILLY AND COMPANY 2010 - 2011
  • Private Grant  awarded by CHIRON CORPORATION 2001 - 2011
  • Education And Training

  • UAB Hospital, Postdoctoral Fellowship
  • Doctor of Medicine, University of Alabama at Birmingham 1987
  • UAB Hospital, Internship 1988
  • UAB Hospital, Residency 1990
  • Full Name

  • Robert Conry